<DOC>
	<DOCNO>NCT02187107</DOCNO>
	<brief_summary>The purpose study primarily ass long-term safety tolerability TMC114/rtv addition individually optimize background antiretroviral therapy HIV-1 infect participant . In addition , antiviral activity immunological effect also evaluate .</brief_summary>
	<brief_title>A Study Assess Long-term Safety Tolerability TMC114/Rtv HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials</brief_title>
	<detailed_description>This phase II , open label , multicenter trial investigational protease inhibitor TMC114 presence ritonavir ( rtv ) HIV-1 infected participant randomize trial TMC114-C201 , TMC114-C207 sponsor select phase I trial might derive benefit TMC114 therapy , judge investigator . The trial consist screening period maximum 4 week , 96-week treatment period 4-week follow-up period . The maximal trial duration participant was104 week . During treatment period , participant receive TMC114 combination RTV , orally , 600/100 mg dose twice daily , addition individually optimize background regimen antiretroviral ( ARV ) therapy , select investigator baseline study . Sponsor provide follow-up treatment TMC114 participant continue benefit treatment TMC114/RTV become commercially available participant . Participants , complete 96 week treatment period TMC114 , opportunity roll extension trial , TMC114 locally commercially available .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Inclusion Criteria Must diagnose HIV Previously randomize trial TMC114C201 , TMC114C207 sponsor select Phase I trials Agreed take least 2 antiretroviral agent baseline onwards Could comply protocol requirement General medical condition , investigator 's opinion , interfere assessment conduct trial A disallowed concomitant therapy Current past history active alcohol and/or drug use Pregnant breastfeeding female Any active unstable medical condition ( e.g. , tuberculosis ; cardiac dysfunction ; pancreatitis ; acute viral infection ) Clinical laboratory evidence active liver disease , liver impairment/dysfunction cirrhosis Clinically significant allergy hypersensitivity excipients investigational medication Laboratory abnormality screen ( criterion variable accord test )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>TMC114</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Norvir</keyword>
	<keyword>Darunavir</keyword>
</DOC>